Granules India Ltd.

NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

530.55 -4.75 (-0.89%)

26.41% Fall from 52W High

1.1M NSE+BSE Volume

NSE 30 May, 2025 3:31 PM (IST)

12,868.2

Market Cap

High in industry

1.1

Beta 1Year

High Volatility

Estimates Beat

Granules India's Q4 net profit and revenue beat Forecaster estimates by 22.6% and 3%, respectively See details

Granules India Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Granules India Ltd. from all sources in a single place.

Load latest

Granules India Ltd.

24 Apr 2020

530.55

-0.89%

Granules India share price rises 6% on USFDA nod

Moneycontrol

Granules now has a total of 26 ANDA approvals from US FDA (24 Final approvals and 2 tentative approvals).

Granules India Ltd. has an average target of 682.00 from 5 brokers.

Granules India Ltd.

24 Apr 2020

530.55

-0.89%

Company Update

GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Granules India Limited announces approval of Trospium Chloride ER Capsules, 60 mg

Granules India Ltd.

23 Apr 2020

530.55

-0.89%

Company Update

GRANULES INDIA LTD.-$ - 532482 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Annual Secretarial Compliance Report under Regulation 24A for the FY 2019-20.

Granules India Ltd.

21 Apr 2020

530.55

-0.89%

Company Update

GRANULES INDIA LTD.-$ - 532482 - Compliance Certificate

BSE India

Compliance Certificate

Granules India Ltd.

21 Apr 2020

530.55

-0.89%

Company Update

GRANULES INDIA LTD.-$ - 532482 - Sub: Submission Of Certificate Under Regulation 40(9) Of SEBI (LODR) …

BSE India

Sub: Submission of Certificate under regulation 40(9) of SEBI (LODR) of Regulations,2015.

Granules India Ltd.

21 Apr 2020

530.55

-0.89%

Company Update

GRANULES INDIA LTD.-$ - 532482 - Statement Of Investor Complaints For The Quarter Ended March 2020

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0990 Name of the Signatory :- CHAITANYA TUMMALADesignation :- Company Secretary and Compliance Officer

Granules India Ltd.

10 Apr 2020

530.55

-0.89%

Company Update

GRANULES INDIA LTD.-$ - 532482 - Shareholding for the Period Ended March 31, 2020

BSE India

Granules India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here

Granules India Ltd.

09 Apr 2020

530.55

-0.89%

Granules India gets USFDA approval for Butalbital, Acetaminophen, Caffeine capsules

Moneycontrol

Granules India Ltd on Thursday said its foreign subsidiary has received approval from the US health regulator for Butalbital, Acetaminophen and Caffeine Capsules used to treat tension headaches.

Granules India Ltd. has gained 16.45% in the last 1 Month

Granules India Ltd.

09 Apr 2020

530.55

-0.89%

Company Update

GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Granules India Limited announces approval of Butalbital, Acetaminophen and Caffeine Capsules USP

Granules India Ltd.

07 Apr 2020

530.55

-0.89%

Company Update

GRANULES INDIA LTD.-$ - 532482 - Granules India'S Visakhapatnam Facility Received EU GMP Approval

BSE India

Granules India's Visakhapatnam facility received EU GMP approval

Is Granules India Ltd. worth buying?

860 Votes:

Buy 84.07%

Sell 10.23%

Hold 5.7%

RESEARCH REPORTS

Accumulate SEE REPORTS >

Buy SEE REPORTS >